Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,983 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T. Ito K, et al. Among authors: asano t. Clin Genitourin Cancer. 2018 Dec;16(6):e1201-e1214. doi: 10.1016/j.clgc.2018.07.028. Epub 2018 Aug 11. Clin Genitourin Cancer. 2018. PMID: 30224330
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M. Shirotake S, et al. Among authors: asano t. Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583. doi: 10.1016/j.clgc.2016.03.014. Epub 2016 Mar 24. Clin Genitourin Cancer. 2016. PMID: 27102405
Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study.
Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, Shinohara N, Asano T. Ito K, et al. Among authors: asano t. Jpn J Clin Oncol. 2020 Oct 22;50(11):1313-1320. doi: 10.1093/jjco/hyaa114. Jpn J Clin Oncol. 2020. PMID: 33089867
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: asano t. Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1. Urol Oncol. 2016. PMID: 27040380
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: asano t. Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4. Urol Oncol. 2017. PMID: 27825515
Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A.
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S. Inokuchi J, et al. Among authors: asano t. World J Urol. 2017 Nov;35(11):1737-1744. doi: 10.1007/s00345-017-2049-x. Epub 2017 May 15. World J Urol. 2017. PMID: 28508102
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.
Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M. Ito K, et al. Among authors: asano t. Jpn J Clin Oncol. 2019 Jan 1;49(1):69-76. doi: 10.1093/jjco/hyy154. Jpn J Clin Oncol. 2019. PMID: 30407543
2,983 results